Expanded and activated natural killer cells for immunotherapy of hepatocellular carcinoma

Cancer Immunology Research

Volumn 4, Issue 7, 2016, Pages 574-581

  Kamiya, Takahiro ^a   Chang, Yu Hsiang ^a,b   Campana, Dario ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; INTERLEUKIN 2; NATURAL KILLER CELL RECEPTOR NKG2D; SORAFENIB; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; NATURAL KILLER CELL; NONHUMAN; SIGNAL TRANSDUCTION; ADOPTIVE IMMUNOTHERAPY; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DRUG SCREENING; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LIVER TUMOR; LYMPHOCYTE ACTIVATION; METABOLISM; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84979771531     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0229     Document Type: Article

References (47)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E86.
2. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379: 1245-55 .
3. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264-73 e1.
4. Rehermann B. Pathogenesis of chronic viral hepatitis: Differential roles of T cells and NK cells. Nat Med 2013;19:859-68.
5. Brechot C, Pourcel C, Louise A, Rain B, Tiollais P. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature 1980;286:533-5.
6. Edman JC, Gray P, Valenzuela P, Rall LB, Rutter WJ. Integration of hepatitis B virus sequences and their expression in a human hepatoma cell. Nature 1980;286:535-8.
7. Sung WK, Zheng H, Li S, Chen R, Liu X, Li Y, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet 2012; 44:765-9.
8. Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol 2014;11:525-35.
9. Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 2015;12:408-24.
10. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell 2015;27: 450-61.
11. Miller JF, Sadelain M. The journey from discoveries in fundamental immunology to cancer immunotherapy. Cancer Cell 2015;27:439-49.
12. Miamen AG, Dong H, Roberts LR. Immunotherapeutic approaches to hepatocellular carcinoma treatment. Liver Cancer 2012;1:226-37.
13. Wirth TC. Spontaneous and therapeutic immune responses in hepatocellular carcinoma: Implications for current and future immunotherapies. Exp Rev Gastroenterol 2014;8:101-10.
14. Gehring AJ, Xue SA, Ho ZZ, Teoh D, Ruedl C, Chia A, et al. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol 2011;55:103-10.
15. Koh S, Shimasaki N, Suwanarusk R, Ho ZZ, Chia A, Banu N, et al. A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus. Mol Ther (Nucleic Acids) 2013;2:e114.
16. Qasim W, Brunetto M, Gehring AJ, Xue SA, Schurich A, Khakpoor A, et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol 2015;62:486-91.
17. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011;331:44-9.
18. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-100.
19. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010;116:2411-9.
20. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in cancer patients. Blood 2005;105: 3051-7.
21. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, et al. NKAML: A pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010;28:955-9.
22. Cui J, Wang N, Zhao H, Jin H, Wang G, Niu C, et al. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int J Cancer 2014;134:342-51.
23. Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 2015;148:1383-91 e6.
24. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005;106:376-83.
25. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009;69:4010-7.
26. Chang YH, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res 2013;73:1777-86.
27. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
28. Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2010;235:267-85.
29. Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM, Hayakawa Y. NKG2D function protects the host from tumor initiation. J Exp Med 2005;202:583-8.
30. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419:734-8.
31. Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 2010;16:3901-9.
32. Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH, et al. Chemokine-driven lymphocyte infiltration: An early intratumoural event determining longterm survival in resectable hepatocellular carcinoma. Gut 2012;61:427-38.
33. Chew V, Tow C, Huang C, Bard-Chapeau E, Copeland NG, Jenkins NA, et al. Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients. J Natl Cancer Inst 2012;104:1796-807.
34. Kamimura H, Yamagiwa S, Tsuchiya A, Takamura M, Matsuda Y, Ohkoshi S, et al. Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence. J Hepatol 2012;56:381-8.
35. Chang CM, Lo CH, Shih YM, Chen Y, WuPY, Tsuneyama K, et al. Treatment of hepatocellular carcinoma with adeno- Associated virus encoding interleukin- 15 superagonist. Hum Gene Ther 2010;21:611-21.
36. Ishiyama K, Ohdan H, Ohira M, Mitsuta H, Arihiro K, Asahara T. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology 2006;43: 362-72.
37. Leboeuf C, Mailly L, Wu T, Bour G, Durand S, Brignon N, et al. In vivo proof of concept of adoptive immunotherapy for hepatocellular carcinoma using allogeneic suicide gene-modified killer cells. Mol Ther 2014;22:634-44.
38. Lapteva N, Durett AG, Sun J, Rollins LA, Huye LL, Fang J, et al. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy 2012;14:1131-43.
39. Krusch M, Salih J, Schlicke M, Baessler T, Kampa KM, Mayer F, et al. The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro. J Immunol 2009;183: 8286-94.
40. Zhang QB, Sun HC, Zhang KZ, Jia QA, Bu Y, Wang M, et al. Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma. PloS One 2013;8:e55945.
41. Sprinzl MF, Reisinger F, Puschnik A, Ringelhan M, Ackermann K, Hartmann D, et al. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology 2013;57:2358-68.
42. Kohga K, Takehara T, Tatsumi T, Ishida H, Miyagi T, Hosui A, et al. Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by downregulating a disintegrin and metalloproteinase 9. Hepatology 2010;51: 1264-73.
43. Sheu AY, Zhang ZL, Omary RA, Larson AC. MRI-monitored transcatheter intra- Arterial delivery of spio-labeled natural killer cells to hepatocellular carcinoma preclinical studies in a rodent model. Invest Radiol 2013; 48:492-9.
44. Leboeuf C, Roser-Schilder J, Lambotin M, Durand S, Wu T, Fauvelle C, et al. Prevention of hepatitis C virus infection by adoptive allogeneic immunotherapy using suicide gene-modified lymphocytes: An in vitro proof-of concept. Gene Ther 2015;22:172-80.
45. Heim MH, Thimme R. Innate and adaptive immune responses in HCV infections. J Hepat 2014;61:S14-S25.
46. Maini MK, Peppa D. NK cells: A double-edged sword in chronic hepatitis B virus infection. Front Immunol 2013;4:57.
47. Ohira M, Ishiyama K, Tanaka Y, Doskali M, Igarashi Y, Tashiro H, et al. Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. J Clin Invest 2009;119:3226-35.